IND Promotion Quandary Again Trips Up Burzynski Research Institute
This article was originally published in The Pink Sheet Daily
Executive Summary
The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.